Success Metrics

Clinical Success Rate
83.6%

Based on 46 completed trials

Completion Rate
84%(46/55)
Active Trials
0(0%)
Results Posted
63%(29 trials)
Terminated
9(15%)

Phase Distribution

Ph phase_2
19
32%
Ph phase_1
12
20%
Ph phase_3
20
33%
Ph not_applicable
1
2%
Ph phase_4
5
8%

Phase Distribution

12

Early Stage

19

Mid Stage

25

Late Stage

Phase Distribution57 total trials
Phase 1Safety & dosage
12(21.1%)
Phase 2Efficacy & side effects
19(33.3%)
Phase 3Large-scale testing
20(35.1%)
Phase 4Post-market surveillance
5(8.8%)
N/ANon-phased studies
1(1.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.0%

46 of 59 finished

Non-Completion Rate

22.0%

13 ended early

Currently Active

0

trials recruiting

Total Trials

60

all time

Status Distribution
Completed(46)
Terminated(13)
Other(1)

Detailed Status

Completed46
Terminated9
Withdrawn4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
60
Active
0
Success Rate
83.6%
Most Advanced
Phase 4

Trials by Phase

Phase 112 (21.1%)
Phase 219 (33.3%)
Phase 320 (35.1%)
Phase 45 (8.8%)
N/A1 (1.8%)

Trials by Status

withdrawn47%
unknown12%
terminated915%
completed4677%

Recent Activity

0 active trials
Showing 5 of 60
completedphase_2

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

NCT01332955
completedphase_4

Telaprevir in Genotype 3 HCV

NCT02087111
completed

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

NCT02333292
completedphase_3

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

NCT00758043
terminatedphase_2

Interaction Between Paroxetine and Telaprevir

NCT01841502
View all 60 trials

Clinical Trials (60)

Showing 20 of 60 trialsScroll for more
NCT01332955Phase 2

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

Completed
NCT02087111Phase 4

Telaprevir in Genotype 3 HCV

Completed
NCT02333292

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

Completed
NCT00758043Phase 3

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Completed
NCT01841502Phase 2

Interaction Between Paroxetine and Telaprevir

Terminated
NCT01080222Phase 2

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Terminated
NCT01821963Phase 3

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Terminated
NCT01598090Phase 3

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

Completed
NCT01854528Phase 3

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults

Completed
NCT01854697Phase 3

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

Completed
NCT01355289Phase 2

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Completed
NCT01657552Phase 1

Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

Completed
NCT01648140Phase 2

Dose Ranging of GSK2336805 in Combination Therapy

Completed
NCT01415141Phase 4

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

Withdrawn
NCT01482390Phase 2

A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Completed
NCT02006745Phase 3

Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)

Completed
NCT01447446

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Completed
NCT02113631Not Applicable

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Completed
NCT01500616Phase 3

Telaprevir Open-Label Study in Co-Infected Patients

Completed
NCT01701063Phase 1

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
60